Start / PharmaTalkRadio / Important business aspects of immuno oncology issues and controversies

PharmaTalkRadio

Important Business Aspects of Immuno-Oncology: Issues and Controversies

44 min • 20 juni 2017

Originally recorded during a panel session at the 2017's Immuno-Oncology 360°, Mark Simon of Torreya Partners moderates the conversation around issues, controversies, and other important business aspects of IO. He's joined by IO360° lead advisor and SVP at GSK, Dr Axel Hoos, Dr Robert Ang of Neon Therapeutics, Dr Jeffrey Bockman from Defined Health, Dr Jeffrey Legos from Novartis Pharmaceuticals, and Dr Chandra Ramanathan at Bayer Healthcare. Save the date for the 4th annual IO360° conference, taking place February 7-9, 2018 in New York City.

Senaste avsnitt

De-Risking Clinical Operations by Taking a Scaffolding Approach to Outsourcing

12 augusti | 28 min

Balancing Between Concentration and Volume when Developing Patient-Centric Biologics

12 augusti | 28 min

Directors' Talk DPHARM 2025 - AI Sessions; Part III

25 juli | 6 min

Innovations in Manufacturing to Make CAR-T More Accessible and Affordable

25 juli | 20 min

Achieving Oral Delivery of Peptides through Formulation and Molecule Design Approaches

25 juli | 29 min

Podcastbild

00:00 -00:00

Podcastbild

00:00 -00:00